Vascular News and Research

RSS

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Using an experimental mouse model for malaria, an international group of scientists has discovered that adding antioxidant therapy to traditional antimalarial treatment may prevent long-lasting cognitive impairment in cerebral malaria. Their findings were published online June 24, 2010, in the journal PLoS Pathogens.

28 Jun 2010

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK.

25 Jun 2010

New research suggests resveratrol may inhibit pathogenic blood vessel formation

Current research suggests that resveratrol, a naturally occurring compound found in red wine, grapes, blueberries, peanuts, and other plants, inhibits pathogenic new blood vessel growth.

25 Jun 2010

IDEV enters exclusive distribution agreement with TriReme for GliderXtreme PTA balloon catheter

IDEV Technologies, Incorporated (IDEV), an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that it has entered into an exclusive distribution agreement covering the U.S. and Germany for TriReme Medical, Inc.'s (TriReme) GliderXtreme™ PTA balloon catheter, an advanced product with specific features for the expanding Peripheral Arterial Disease (PAD) market.

24 Jun 2010

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Researchers at UT Southwestern Medical Center have pinpointed a set of biological mechanisms through which estrogen confers its beneficial effects on the cardiovascular system, independent of the hormone's actions on cancer. Their investigation suggests that drugs targeting a specific subpopulation of estrogen receptors found outside the cell nucleus might activate the cardiovascular benefits of estrogen without increasing cancer risk.

24 Jun 2010

Kensey Nash, St. Jude Medical sign two-year Supply Agreement

Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.

24 Jun 2010

Scientists discover septet of overactive genes that control bodily function

In what is believed to be the largest review of the human genetic code to determine why some people's blood platelets are more likely to clump faster than others, scientists at Johns Hopkins and in Boston have found a septet of overactive genes, which they say likely control that bodily function.

23 Jun 2010

BioDigital, NYU Langone partner to create Right Upper Lobe Resection Cognitive Task Trainer

SensAble Technologies, a leader in haptic devices and 3D modeling solutions, announced that its customer, BioDigital, working in partnership with surgeons at NYU Langone Medical Center, has created the first medical simulation application for teaching residents the high-technology procedure for lung resection of the right upper lobe, most commonly performed to treat resectable lung cancers.

23 Jun 2010

Infusion Nurses Society paper states role of RNs in using IO access devices

The American Association of Critical-Care Nurses recently endorsed "The Role of the Registered Nurse in the Insertion of Intraosseous Access Devices," an official position paper from the Infusion Nurses Society, Norwood, Mass.

23 Jun 2010

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Patients who had experienced a heart attack and lowered their blood homocysteine levels with folic acid and vitamin B12 supplementation did not have an associated lower risk of heart attack, coronary death or stroke, according to a study in the June 23/30 issue of JAMA. However, the researchers did find that folic acid supplementation did not increase the risk of cancer, which has been speculated.

23 Jun 2010

Excessive, uncontrolled vascular growth leads to development of cavernomas: Researchers

Benign vascular malformations known as cavernomas can occur in many tissues of the body. These abnormalities are characterized by enlarged, instable and unstructured blood vessels. Cavernomas of medical relevance are primarily those of the brain, which develop approximately in one out of two hundred people. In the brain, such growths often remain unnoticed and are typically found by chance in MRI scans. If they grow larger, they often cause unspecific symptoms such as headaches or dizziness.

23 Jun 2010

Survey: MegaRed Omega-3 Krill Oil recommended for overall cardiovascular health

With America focused on the future of healthcare, a recent survey provides Americans added confidence in the ability of supplements like MegaRed Omega-3 Krill Oil to support their overall cardiovascular health.

23 Jun 2010

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Long-term data presented today from Ardian's SYMPLICITY HTN-1 study demonstrate that the significant reductions in blood pressure achieved using Renal Denervation treatment are sustained through 24 months. The data were presented at the late breaking trials session of the European Society of Hypertension Annual Scientific meeting in Oslo, Norway.

22 Jun 2010

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Pulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure.

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. One of the grants supports the first large, multi-center, randomized clinical trial to compare outcomes in heart surgery patients who receive transfusions of red blood cells that have been stored for shorter or longer amounts of time.

22 Jun 2010

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.

22 Jun 2010

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Boston Scientific Corporation today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation System, including balloon lengths of 120 and 150 mm. The PolarCath System is used to restore blood flow in patients with critical limb ischemia (severe blockages in the arteries below the knee) and blockages in the femoral and popliteal (behind the knee) arteries. Both conditions result from peripheral artery disease.

21 Jun 2010

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced that the U.S. Food & Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM G3™ SF (Small Fixed), the newest version of its peripheral revascularization catheter for the treatment of PVD.

21 Jun 2010

Vascular News and Research

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

New research suggests resveratrol may inhibit pathogenic blood vessel formation

IDEV enters exclusive distribution agreement with TriReme for GliderXtreme PTA balloon catheter

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Kensey Nash, St. Jude Medical sign two-year Supply Agreement

Scientists discover septet of overactive genes that control bodily function

BioDigital, NYU Langone partner to create Right Upper Lobe Resection Cognitive Task Trainer

Infusion Nurses Society paper states role of RNs in using IO access devices

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Excessive, uncontrolled vascular growth leads to development of cavernomas: Researchers

Survey: MegaRed Omega-3 Krill Oil recommended for overall cardiovascular health

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

Women who experience early menopause may have cardiovascular disease later in life: Study

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News